Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Friedlander TW, et al. Among authors: sharib j. Urol Oncol. 2012 Jul-Aug;30(4):408-14. doi: 10.1016/j.urolonc.2010.06.014. Epub 2010 Oct 2. Urol Oncol. 2012. PMID: 20884247 Clinical Trial.
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Rosenberg JE, et al. Among authors: sharib j. J Clin Oncol. 2009 Jun 10;27(17):2772-8. doi: 10.1200/JCO.2008.19.8002. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349545 Free PMC article.
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Harzstark AL, et al. Among authors: sharib j. Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29. Cancer. 2011. PMID: 24048789 Free article. Clinical Trial.
Comparison of Latino and non-Latino patients with Ewing sarcoma.
Sharib J, Horvai A, Gray Hazard FK, Daldrup-Link H, Goldsby R, Marina N, DuBois SG. Sharib J, et al. Pediatr Blood Cancer. 2014 Feb;61(2):233-7. doi: 10.1002/pbc.24745. Epub 2013 Aug 23. Pediatr Blood Cancer. 2014. PMID: 23970433 Free PMC article.
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.
Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ. Moroz A, et al. Among authors: sharib jm. Clin Cancer Res. 2020 Jul 15;26(14):3608-3615. doi: 10.1158/1078-0432.CCR-20-0268. Epub 2020 Apr 27. Clin Cancer Res. 2020. PMID: 32341034 Free PMC article.
Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts.
Ivry SL, Sharib JM, Dominguez DA, Roy N, Hatcher SE, Yip-Schneider MT, Schmidt CM, Brand RE, Park WG, Hebrok M, Kim GE, O'Donoghue AJ, Kirkwood KS, Craik CS. Ivry SL, et al. Among authors: sharib jm. Clin Cancer Res. 2017 Aug 15;23(16):4865-4874. doi: 10.1158/1078-0432.CCR-16-2987. Epub 2017 Apr 19. Clin Cancer Res. 2017. PMID: 28424202 Free PMC article.
26 results